IPAROMLIMAB AND TUVONRALIMAB

Clinical trials for IPAROMLIMAB AND TUVONRALIMAB explained in plain language.

Never miss a new study

Get alerted when new IPAROMLIMAB AND TUVONRALIMAB trials appear

Sign up with your email to follow new studies for IPAROMLIMAB AND TUVONRALIMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Drug combo aims to make risky kidney cancer surgery safer

Disease control Recruiting now

This study is testing whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted drug (lenvatinib) can shrink kidney tumors before surgery. The goal is to make a kidney-sparing operation possible and safer for 25 patients whose tumors are curr…

Matched conditions: IPAROMLIMAB AND TUVONRALIMAB

Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

IPAROMLIMAB AND TUVONRALIMAB

Get alerted when new IPAROMLIMAB AND TUVONRALIMAB trials appear

Drug combo aims to make risky kidney cancer surgery safer